Please login to the form below

Not currently logged in
Email:
Password:

Retrophin

This page shows the latest Retrophin news and features for those working in and with pharma, biotech and healthcare.

Retrophin rockets away as rare disease trial hits targets

Retrophin rockets away as rare disease trial hits targets

What a difference a year makes. Under pressure in 2015, US firm Retrophin now has a positive trial in hand for a rare disease drug that some analysts say could approach ... Last year, Retrophin was indirectly caught up in the scandal surrounding its

Latest news

More from news
Approximately 3 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    More recently Retrophin sold its PRV to Sanofi for $245m, so it looks as though values are definitely on the rise!

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi purchased the paediatric PRV from Retrophin for the total consideration of $245m ($150m on closure with two subsequent payments in 2016 and 2017 of $47.7m). ... 300. Retrophin/ Sanofi. Acquisition of priority review voucher [PRV]. For Cholbam

  • Deal Watch table for February 2014 Deal Watch table for February 2014

    Licence termination. DiaPep277 for type 1 diabetes patients. 72. Manchester Pharmaceuticals / Retrophin.

  • Pharma deals during February 2014 Pharma deals during February 2014

    Recently public, Retrophin has acquired Manchester Pharmaceuticals, a speciality pharmaceutical company that focuses on treatments for rare diseases. ... Retrophin is paying a total of $62.5m, including an upfront of $29.5m, plus royalties based on

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Amryt Pharma appoints new regulatory affairs head Amryt Pharma appoints new regulatory affairs head

    Derval O’Carroll joins the rare disease-focused biopharma from Retrophin. Rare and orphan disease-focused biopharmaceutical group Amryt Pharma has appointed a new head of regulatory affairs in the form ... Prior to joining Amryt, she served as senior

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics